Literature DB >> 18816110

Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.

Konstantina Vougogiannopoulou1, Yoan Ferandin, Karima Bettayeb, Vassilios Myrianthopoulos, Olivier Lozach, Yunzhen Fan, Carl Hirschie Johnson, Prokopios Magiatis, Alexios-Leandros Skaltsounis, Emmanuel Mikros, Laurent Meijer.   

Abstract

Glycogen synthase kinase -3 (GSK-3) is a key enzyme involved in numerous physiological events and in major diseases, such as Alzheimer's disease, diabetes, and cardiac hypertrophy. Indirubins are bis-indoles that can be generated from various natural sources or chemically synthesized. While rather potent and selective as GSK-3 inhibitors, most indirubins exhibit low water solubility. To address the issue of solubility, we have designed novel analogues of 6-bromo-indirubin-3'-oxime with increased hydrophilicity based on the GSK-3/indirubins cocrystal structures. The new derivatives with an extended amino side chain attached at position 3' showed potent GSK-3 inhibitory activity, enhanced selectivity, and dramatically increased water solubility. Furthermore, some of them displayed little or no cytotoxicity. The new indirubins inhibit GSK-3 in a cellular reporter model. They alter the circadian period measured in rhythmically expressing cell cultures, suggesting that they might constitute tools to investigate circadian rhythm regulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18816110      PMCID: PMC2717725          DOI: 10.1021/jm800648y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  46 in total

Review 1.  Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation.

Authors:  Laura Dugo; Marika Collin; Christoph Thiemermann
Journal:  Shock       Date:  2007-02       Impact factor: 3.454

Review 2.  GSK-3 inhibitors for Alzheimer's disease.

Authors:  Jesús Avila; Félix Hernández
Journal:  Expert Rev Neurother       Date:  2007-11       Impact factor: 4.618

Review 3.  Structure-based approaches in the design of GSK-3 selective inhibitors.

Authors:  Dhilon S Patel; Nigus Dessalew; Pansy Iqbal; Prasad V Bharatam
Journal:  Curr Protein Pept Sci       Date:  2007-08       Impact factor: 3.272

Review 4.  Schizophrenia as a GSK-3 dysregulation disorder.

Authors:  Simon Lovestone; Richard Killick; Marta Di Forti; Robin Murray
Journal:  Trends Neurosci       Date:  2007-02-26       Impact factor: 13.837

Review 5.  GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.

Authors:  Michael K Rowe; Charlotte Wiest; De-Maw Chuang
Journal:  Neurosci Biobehav Rev       Date:  2007-03-15       Impact factor: 8.989

Review 6.  CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases.

Authors:  S H Obligado; O Ibraghimov-Beskrovnaya; A Zuk; L Meijer; P J Nelson
Journal:  Kidney Int       Date:  2007-12-19       Impact factor: 10.612

7.  An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins.

Authors:  Vassilios Myrianthopoulos; Prokopios Magiatis; Yoan Ferandin; Alexios-Leandros Skaltsounis; Laurent Meijer; Emmanuel Mikros
Journal:  J Med Chem       Date:  2007-08-01       Impact factor: 7.446

Review 8.  Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?

Authors:  D Muyllaert; A Kremer; T Jaworski; P Borghgraef; H Devijver; S Croes; I Dewachter; F Van Leuven
Journal:  Genes Brain Behav       Date:  2008-02       Impact factor: 3.449

Review 9.  The GSK3 hypothesis of Alzheimer's disease.

Authors:  Claudie Hooper; Richard Killick; Simon Lovestone
Journal:  J Neurochem       Date:  2007-12-18       Impact factor: 5.372

10.  Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance.

Authors:  Katsuya Tanabe; Zhonghao Liu; Satish Patel; Bradley W Doble; Lin Li; Corentin Cras-Méneur; Sara C Martinez; Cris M Welling; Morris F White; Ernesto Bernal-Mizrachi; James R Woodgett; M Alan Permutt
Journal:  PLoS Biol       Date:  2008-02       Impact factor: 8.029

View more
  33 in total

1.  Early growth response-1 induction by fibroblast growth factor-1 via increase of mitogen-activated protein kinase and inhibition of protein kinase B in hippocampal neurons.

Authors:  Alexander H Benz; Mehdi Shajari; Natalie Peruzki; Faramarz Dehghani; Erik Maronde
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Circadian rhythmicity of active GSK3 isoforms modulates molecular clock gene rhythms in the suprachiasmatic nucleus.

Authors:  Rachel C Besing; Jodi R Paul; Lauren M Hablitz; Courtney O Rogers; Russell L Johnson; Martin E Young; Karen L Gamble
Journal:  J Biol Rhythms       Date:  2015-02-27       Impact factor: 3.182

3.  From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity.

Authors:  Emilie Durieu; Eric Prina; Olivier Leclercq; Nassima Oumata; Nicolas Gaboriaud-Kolar; Konstantina Vougogiannopoulou; Nathalie Aulner; Audrey Defontaine; Joo Hwan No; Sandrine Ruchaud; Alexios-Leandros Skaltsounis; Hervé Galons; Gerald F Späth; Laurent Meijer; Najma Rachidi
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.

Authors:  Luminita Crisan; Sorin Avram; Liliana Pacureanu
Journal:  Mol Divers       Date:  2017-01-21       Impact factor: 2.943

5.  Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling.

Authors:  Sangkil Nam; Anna Scuto; Fan Yang; Wenyong Chen; Sungman Park; Hwa-Seung Yoo; Heiko Konig; Ravi Bhatia; Xinlai Cheng; Karl-Heinz Merz; Gerhard Eisenbrand; Richard Jove
Journal:  Mol Oncol       Date:  2012-02-17       Impact factor: 6.603

Review 6.  Circadian clock control of endocrine factors.

Authors:  Karen L Gamble; Ryan Berry; Stuart J Frank; Martin E Young
Journal:  Nat Rev Endocrinol       Date:  2014-05-27       Impact factor: 43.330

Review 7.  Chronobiology of bipolar disorder: therapeutic implication.

Authors:  Sara Dallaspezia; Francesco Benedetti
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

8.  High-throughput screening and chemical biology: new approaches for understanding circadian clock mechanisms.

Authors:  Tsuyoshi Hirota; Steve A Kay
Journal:  Chem Biol       Date:  2009-09-25

9.  MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells.

Authors:  Lucy Liu; Nicolas Gaboriaud; Konstantina Vougogianopoulou; Yan Tian; Jun Wu; Wei Wen; Leandros Skaltsounis; Richard Jove
Journal:  Cancer Biol Ther       Date:  2013-11-01       Impact factor: 4.742

10.  Agonism of Wnt-β-catenin signalling promotes mesenchymal stem cell (MSC) expansion.

Authors:  Michael D Hoffman; Danielle S W Benoit
Journal:  J Tissue Eng Regen Med       Date:  2013-04-01       Impact factor: 3.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.